Boston Scientific (BSX) Net Equity Issued and Repurchased (2009 - 2020)

Boston Scientific (BSX) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $933.0 million in Q2 2020.

• For the quarter ending Q2 2020, Net Equity Issued and Repurchased rose 1860.38% year-over-year to $933.0 million; the trailing twelve-month figure through Sep 2021 stood at $933.0 million (down 4.31% YoY), and the FY2020 full-year result was $975.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased climbed to $933.0 million in Q2 2020, from $42.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $933.0 million in Q2 2020 to a low of -$94.0 million in Q4 2018.
• A 5-year average of $73.2 million and a median of $34.0 million in 2016 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 1666.67% in 2018 and surged 1860.38% in 2020, its largest moves.
• Tracing BSX's Net Equity Issued and Repurchased over 5 years: stood at $3.0 million in 2016, then surged by 100.0% to $6.0 million in 2017, then sank by 1666.67% to -$94.0 million in 2018, then surged by 43.62% to -$53.0 million in 2019, then surged by 1860.38% to $933.0 million in 2020.
• Business Quant data shows BSX's Net Equity Issued and Repurchased at $933.0 million in Q2 2020, $42.0 million in Q1 2020, and -$53.0 million in Q2 2019.